The development and subsequent validation of an in vitro-in vivo correlation (IVIVC) is an increasingly important component of extended release dosage form optimization. An IVIVC is a relationship (preferable linear) between a biological parameters (C max , T max , or AUC) produced by a dosage form and an in vitro characteristics (e.g., in vitro dissolution).
The development and subsequent validation of an in vitro-in vivo correlation (IVIVC) is an increasingly important component of extended release dosage form optimization. An IVIVC is a relationship (preferable linear) between a biological parameters (C max , T max , or AUC) produced by a dosage form and an in vitro characteristics (e.g., in vitro dissolution). 1) The in vitro dissolution curve is usually determined by a suitable dissolution test and in vivo absorption curve is frequently determined by deconvolution using model dependent (e.g., Wagner-Nelson or Loo-Regleman) or model independent (e.g., DeMons) methods. 2, 3) Level A, B, C and multiple Level C correlation has been described by the Food and Drug Administration (FDA) for IVIVC. The highest level correlation, Level A, is usually linear and is a direct relationship between the amounts of drug dissolved and the amount of drug absorbed. 1, 4, 5) The recent in vitro-in vivo correlation guidance developed by the FDA, states that the main objective of developing and evaluating an IVIVC is to enable the dissolution test to serve as a surrogate for in vivo bioavailability studies. This may reduce the numbers of bioequivalence studies required for approval as well as during scale-up and post approval change. 5) There are numerous examples of Level A correlations in the literature, however many fall short in assessing the predictability of the correlation. The process for the development and validation of an IVIVC has been outlined in the FDA IVIVC guidance.
5) The development of the correlation usually involves the following three steps: (1) develop formulation with different release rates, e.g.
slow, moderate and fast, (2) obtain in vitro dissolution profiles and in vivo plasma concentration profiles for these formulations, and (3) estimate the in vivo absorption or in vitro dissolution time course using an appropriate deconvolution technique for each formulation. The internal validation 5) of the correlation focuses on using prediction error metrics to determine how well the IVIVC model predict the plasma concentration profile of those formulations used to develop the correlation.
Establishing a correlation between the in vivo plasma concentration profile and in vitro dissolution profile of an extended release formulation has been great interest for a number of years. Extended release of drugs in the gastrointestinal tract following oral administration is the intended rate-limiting factor in the absorption process. It is therefore desirable to use in vitro data to predict in vivo bioavailability parameters for the rational development and evaluation process for extended-release dosage forms. 6, 7) Glipizide (N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]-ethyl]-5-methyl-pyridine-2-carboxamide) is a hypoglycemic agent of the sulfonylurea group. 8) Numerous IVIVC studies of extended release formulation have been previously reported, [9] [10] [11] [12] [13] [14] although there are none involving extended release glipizide formulations. Therefore, the purpose of this study was to develop an IVIVC for three novel hydrophilic matrix extended release glipizide 5 mg tablets. The validity of the correlation was established through the external predictability approach, by using the data from one study to predict the plasma concentration of a similar dosage form, with different rate of release. Formulations Three extended-release matrix formulations of 5 mg glipizide were developed by non aqueous wet granulation method using hydroxypropyle methylcellulose (HPMC K 4M, HPMC K 15M and HPMC K 100M) as the release-rate-controlling exciepient. Lactose (grade 315, 316) was used as filler and magnesium stearate, talcum powder and Aerosil as lubricant. These formulations were designed to release glipizide at three different rates, referred as fast (release up to 12 h), moderate (release up to 18 h) and slow (release up to 24 h). The high-viscosity HPMC (K 100M), medium-viscosity HPMC (K 15M) and low-viscosity HPMC K 4M) were used for slow, moderate and fast release, respectively. Final weight of the fast release formulation was 160 mg with average hardness of 5.0 kg cm
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. The average weight of the moderate release formulation was 190 mg with an average hardness of 6.0 kg cm
. The average weight of the slow release formulation was 220 mg with an average hardness of 7.0 mg cm
. External validation was carried out based on the data obtained from the extended-release matrix tablet designed to release up to 15 h, optimized by using response surface methodology (RSM). This optimized formulation was comprised of mixture of low viscosity grade of hydroxypropyle methylcellulose (HPMC K 4M) and medium viscosity grade of hydroxypropyle methylcellulose (HPMC K 15M) and the average weight and hardness was 180 mg and 6.5 kg cm Ϫ2 respectively. Dissolution Testing The dissolution behavior of glipizide extended-release matrix tablets (fast, moderate and slow) was continuously recorded using a semi-automatic dissolution apparatus (Electrolab, USPXXIII, TDT 06P). The release characteristics of the formulations were determined using United States Pharmacopeia (USP) Apparatus II at 50 and 100 rev. min Ϫ1 in 0.1 M HCl or pH 6.8 phosphate buffer maintained at 37°C. Dissolution tests were performed on six tablets and the amount of drug release was analyzed by validated reverse phase high performance liquid chromatography (HPLC) method at 275 nm. Dissolution samples were collected at the following times: 0, 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 12, 18 and 24 h.
Bioavailability Study The bioavailability study was an open level, fasting, single dose and four-way cross over study (nϭ6) using normal healthy subjects. Subjects provided informed consent to participate in the study. The study was approved by the Institution ethical committee of Jadavpur University, Kolkata, India. Twenty four male, non smoking subjects were enrolled in the study and received three extendedrelease 5 mg glipizide matrix tablets (fast, moderate and slow), once per day. All three formulations were given in a randomized fashion. In addition to the extended release formulations, an immediate-release 5 mg glipizide tablet (GLIPY, manufactured by Alembic, India) was also administered. In order of drug administration was randomized in four sequences (ABCD, BADC, CDBA and DCAB) in blocks of four. Blood samples were obtained at seventeen time points from pre dose (0 h) until 48 h post dose (0, 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 12, 18, 24, 48 h). Subjects fasted for 12 h prior to administration of drugs. A washout period of 1 week was allowed between dose administrations. The plasma samples were stored at Ϫ20°C until assayed.
Assay Method for Glipizide An analytical method for the determination of glipizide and gliclazide (as internal standard) in human plasma was developed and validated using high performance liquid chromatography (HPLC; Model No. K 2501; Knauer, Germany, Eurochrom software). The method determined the concentrations of glipizide using a calibration range of 0.02-1.0 mg ml
Ϫ1
. The accuracy of the assay for glipizide (as determined from the calibration standards and control samples) was in the range 98.12-102.34% and 98.28-101.59%, respectively.
In Vitro Dissolution Data Analysis The in vitro dissolution data was analyzed by estimation of a similarity factor, the f 2 metric and parameterized by the sigmoid Emax model. The dissolution profiles were compared using the similarity factor, f 2 presented in the following equation . 15) (1)
Where R t and T t are the cumulative percent dissolved at each time point for the reference product and the test product, respectively. FDA has set a public standard of 50Ͻf 2 Ͻ100 to indicate similarity between two dissolution profiles.
In Vivo Data Analysis The glipizide concentration-time data were evaluated by analysis of plasma samples by validated HPLC method. The measured plasma concentrations were used to calculate the area under the plasma concentration-time profile from time zero to last concentration time point (AUC 0-t ). The AUC 0-t was determined by the trapezoidal method. Area under the plasma concentration-time curve from zero to infinity (∞), AUC 0-∞ , was determined by the following equation:
Where K e , the elimination rate constant, was estimated by fitting the logarithm of the concentration versus time to a straight line over the observed exponential decline. The Wagner-Nelson method 16) was used to calculate the percentage of the glipizide dose absorbed:
Where, F(t) is the amount absorbed. The percent of dose absorbed is determined by dividing the amount absorbed at any time by the plateau value, K e AUC (0-∞) and multiplying this ratio by 100.
%dose absorbedϭ[{c(t)ϩK e AUC 0-t }/K e AUC 0-∞ ]ϫ100 (4) In Vitro-in Vivo Correlation The data generated in the bioavailability study were used to develop the IVIVC. The percent of drug dissolved was determined using the aforementioned dissolution testing method and the fraction of drug absorbed was determined using the method of Wag-
ner-Nelson 16) from the glipizide plasma concentration vs. time data following the slow, moderate and fast releasing formulations. The deconvolution procedure was used to obtain in vivo input profiles of glipizide using immediate-release data as the reference treatment. Correlation models were developed using mean fraction dissolved and mean fraction absorbed data from various combinations of the formulations including: (1) slow, moderate and fast (S/M/F), (2) slow and fast (S/F), (3) moderate and fast (M/F) and (4) slow and moderate (S/M) formulations. Linear regression analysis was used to examine the relationship between percent of drug dissolved and percent of drug absorbed. The percent of drug unabsorbed was calculated from the percent absorbed. The percent of drug unabsorbed versus time was plotted on a semi log paper. The slope of the best-fit line for the semi-log treatment of this data was taken as the first order rate constant for absorption (K a ) where slope is equal to negative K a divided by 2.303, the dissolution rate constant (K diss ) was determined from percent cumulative released versus the square root of time. Linear regression analysis was applied to the IVIVC plots and coefficient of determination (R 2 ), slope and intercept values were calculated.
Internal Validation of the IVIVC The internal validation or predictability is defined as how well four IVIVC models described the data used to develop the model. The internal validation was based on how well the defining four IVIVC models (i.e., S/M, S/F, M/F and S/M/F) predicted the in vivo performance of each formulation (i.e., slow, moderate and fast). The procedure used for the internal validation was as follows: the S/M, S/F, M/F and S/M/F IVIVC models were used to predict the in vivo performance of the slow, moderate and fast formulations, respectively. Cross validation was also used to evaluate predictability and it occurred when the IVIVC model did not contain the formulation being predicted. One formulation (i.e., F, S or M) was left out and the in vivo plasma glipizide concentration vs. time profile was determined from the IVIVC correlation obtained from the remaining two formulations (i.e., S/M, M/F or S/F, respectively).
The IVIVC model predicted glipizide plasma concentration was determined by the following procedure. First, best fitting line was drawn between the cumulative percent dissolved and square root of time. The slope of the best fitting line was used as rate of dissolution. The in vitro dissolution rates were then converted to in vivo dissolution rates by using the different (S/M, S/F, M/F and S/M/F) IVIVC models (i.e., slope, intercept). The prediction of the plasma glipizide concentrations from the corresponding in vivo dissolution profiles was accomplished by convolution of the in vivo dissolution rates and the pharmacokinetic model for the immediate release administration of the drug.
The prediction of the plasma glipizide concentration was accomplished using the following curve fitting equation:
Where yϭpredicted plasma concentration (ng ml Ϫ1 ); const.ϭ the constant representing F/V d , where Fϭfraction absorbed, and V d is the apparent volume of distribution; K a ϭabsorption rate constant; K e ϭoverall elimination rate constant. The deconvolution was accomplished on a spread sheet in Excel.
To further assess the predictability and the validity of the correlations, we determined observed and IVIVC model-predicted C max and AUC 0-∞ values for each formulation. The percent prediction errors for C max and AUC 0-∞ were calculated as follows:
%PE AUC ϭ[{AUC (obs) ϪAUC (pred) }/AUC (obs) ]ϫ100
Where C max(obs) and C max(pred) are the observed and IVIVC model predicted maximum plasma concentration, respectively; and AUC (obs) and AUC (pred) are the observed and IVIVC model-predicted AUC 0-∞ for the plasma concentration profiles, respectively. The IVIVC was considered valid if the average absolute % prediction error is Ͻ10 for C max and AUC and if the % prediction error for each formulation does not exceed 15%. External Validation of the IVIVC The external validation was accomplished by the optimized extended-release matrix formulation of glipizide containing 5 mg active ingredient, selected to provide a C max of the reformulated product equivalent to the C max obtained from the fast, moderate and slow tablets, and to re-test the re-formed product against the fast, moderate and slow tablets in another bioavailability study in human subjects.
Statistical Analysis All the results were expressed as meanϮstandard deviation (S.D.). The values of C max , T max and AUC 0-∞ obtained from three formulations were analyzed using one-way analysis of variance with WinNonlin (version 4.1, Pharsight) software to determine statistically significant differences. The AUC 0-∞ and C max values were logarithmically transformed before statistical analysis. pՅ0.5 denoted statistical significance.
RESULTS AND DISCUSSION
In Vitro Studies Mean profiles of the cumulative glipizide fraction dissolved from the slow, moderate and fast formulation are illustrated in Figs. 1 and 2 . The dissolution testing methods were Apparatus II, pH 6.8 phosphate buffers at 50 and 100 rev. min Ϫ1 (Fig. 1) , Apparatus II, 0.1 M HCl at 50 and 100 rev. min Ϫ1 (Fig. 2) . The associated f 2 metrics, which determines the similarity of the various formulations are shown in Table 1 . A f 2 value between 50 and 100 suggests that two profiles are similar. Eddington et al. (1998) reported that it is imperative to utilize a dissolution methodology that discriminates between formulations and the mimics the in vivo release profile in the process of developing an IVIVC. 9) Accordingly, Apparatus II, pH 6.8 at 100 rev. min Ϫ1 were found to be the most discriminating dissolution methods. In Vivo Studies Twenty four male subjects completed the study. The meanϮS.D. age, height and weight of the subjects were 32.8Ϯ5.4 years, 168.5Ϯ15.2 cm and 58.3Ϯ4.9 kg, respectively. There were no serious adverse reactions reported in the study. Mean pharmacokinetic parameters are summarized in Table 2 and mean glipizide plasma concentration versus time profiles after each formulation and the immediate-release formulation are presented in Fig. 3 . The rank order of release observed in the dissolution testing was also apparent in the plasma glipizide concentration profiles with a mean C max of 451.529, 439.609, and 411.957 ng/ml for the slow, moderate and fast releasing formulations. In addition, a rank order was also apparent in the AUC 0-∞ ( Table 2 ). The AUC 0-∞ from immediately release tablets (2059.316Ϯ 43.821 ng · h · ml Ϫ1 ) was somewhat less than the AUC 0-∞ from the extended release formulation (pϽ0.05), probably due to shorter residence time of the immediately release tablet than the extended release tablets or drug-excipient interaction from the immediate release tablet, which decreased the bioavailability of the immediate release tablet.
IVIVC Correlation Development A Level A IVIVC was investigated using the percent absorbed data versus percent dissolved for both the fast, moderate and slow formulations, using both 0.1 M HCl and pH 6.8 phosphate buffer dissolution media at 50 rev. min Ϫ1 and 100 rev. min Ϫ1 . A good linear regression relationship was observed between the percent dissolved in the dissolution testing using phosphate buffer pH 6.8 at 50 rev. min Ϫ1 and the percent absorbed for the combined data of the three dosage (yϭ3.3863xϪ2.5871; correlation coefficient (r 2 )ϭ0.9483). Another good linear regression relationship was observed between the percent dissolved in the dissolution testing using phosphate buffer pH 6.8 at 100 rev. min Ϫ1 and the percent absorbed for the combined data of the three dosage (yϭ2.8008xϪ5.1494; correlation coefficient (r 2 )ϭ0.9522). It was also observed that the in vivo absorption rate constant, K a values for slow, moderate and fast formulations correlated with the dissolution rate constant, K diss values of the pH 6.8 phosphate buffer at 100 rev. min
Ϫ1
. Dissolution testing using pH 6.8 phosphate buffers at 100 rev. min Ϫ1 was more representative of the in vivo absorption profiles and linear regression relationships were developed. There was good linear correlation for these models, with r 2 values Ͼ0.95 for the IVIVC models. Each correlation was found to be significant and the combination of the fast and slow formulation displayed the strongest relationship (r 2 ϭ0.9982). Conversely, the correlation for the slow and moderate formulations was less descriptive as compared to other correlation models (r 2 ϭ0.9689).
Internal Validation
The internal validation was performed by convolution of the dissolution data (i.e., pH 6.8 phosphate buffers at 100 rev. min
Ϫ1
) that corresponded to each formulation (S/M/F). Each of the IVIVC model predicted glipizide plasma concentration versus time profiles were compared to the experimental data points using prediction error metrics. The validity of the correlations was also assessed by determining how well the IVIVC models could predict the rate and extent of glipizide absorption as characterized by C max and AUC 0-∞ . Tables 3 and 4 present the errors estimated for the difference between the observed and predicted C max and AUC 0-∞ values for all the IVIVC models. None of the IVIVC model predicted parameters deviated from the experimental values by more than 10%.
External Validation The external validation was accomplished by the optimized extended-release matrix formulation of glipizide containing 5 mg active ingredient and to predict the plasma concentration of the new formulation all four IVIVC models (S/M/F, S/M, M/F and S/F) were used. The actual (observed) maximum average plasma concentration of the new formulation at steady state was determined to be 446.059Ϯ38.431 ng/ml by in vivo study (nϭ6). The errors estimated for the difference between the observed and predicted C max and AUC 0-∞ values of the new formulation for all the IVIVC models ranged between (Ϫ)8.91 to 7.02% and (Ϫ)5.59 to 6.17%, respectively.
Discussion The FDA-IVIVC Guidance and the USP/ AAPS/FDA-Workshop II, which examined the scale-up of oral extended release dosage forms, stated that the objective of an IVIVC was the use of dissolution as a surrogate for bioequivalency testing and as an aid in setting dissolution specifications. In the process of developing an IVIVC, it is imperative to utilize dissolution methodology that discriminates between formulations and mimics the in vivo release profiles. We examined the various dissolution testing methods to characterize the release of the three formulations of glipizide. The initial IVIVC development began with using the USP defined dissolution methodology for glipizide (i.e. Apparatus II, phosphate buffer pH 6.8 at 50 rev. min Ϫ1 ). These dissolution methods produced a curvilinear relationship (Fig. 4A) between percentage dissolved and percentage absorbed and the dissolution results were not representative of the in vivo glipizide absorption profile. The release profile generated lagged behind the absorption profile. An increase in the shear force or velocity of the testing system was required to approximate the absorption profile. Dissolution testing with Apparatus II, phosphate buffer pH 6.8 at 100 rev. min Ϫ1 provided percentage dissolved data that was predictive of the percentage absorbed data (Fig. 4B) . It appears that the increase in agitation generated from this in vitro dissolution system appropriately simulated the erosion that occured in vivo with this formulation. Once identified, the dissolution methodology should be used in any further evaluation of the correlation, such as external validation. Correlations were developed with the slow, moderate and fast formulations as well as combinations of two formulations (e.g., slow and moderate, moderate and fast, slow and fast). The evaluation of the correlation displayed a significant linear relationship between percentage dissolved and percentage absorbed when using either two (S/M, M/F or S/F) or three (S/M/F) formulations. The IVIVC relationship was demonstrated consistently with a minimum of two formulations as well as three formulations.
The predictability of the correlations developed was tested by internal validation which consisted of calculating percentage prediction errors (%PE C max and %PE AUC 0-∞ ). The realistic measurement of the validation is the ability of the IVIVC models to estimate the observed rate and extent of absorption. All IVIVC models predicted the observed C max and AUC 0-∞ within 10% (Tables 3, 4 ). The lowest percent prediction error for C max (2.63%) was found for the slow formulation using the S/F IVIVC model. The S/F IVIVC model provided the best estimate of AUC 0-∞ for the fast formulation (2.59%). The relatively low percent prediction errors (C max and AUC 0-∞ ) found strongly suggest that the glipizide IVIVC are valid. The average percent prediction error of less than 10% indicates that the correlation is predictive and is acceptable according to the FDA-IVIVC guidance.
